La información más actual para el médico de familia
Prensa Tema Resúmenes Revistas Internet Usuarios registrados | Quiénes somos
Más actualidad
Búsqueda avanzada


(Semana 23/03/2015 - 29/03/2015)

BMJ-British Medical Journal. Vol. 350. Núm. 8001


Power MC, Kioumourtzoglou M, Hart JE, Okereke OI, Laden F, Weisskopf MGThe relation between past exposure to fine particulate air pollution and prevalent anxiety: observational cohort study. Págs. h1111 TC PDF 

Shah AS, Lee KK, McAllister DA, Hunter A, Nair H, Whiteley W et alShort term exposure to air pollution and stroke: systematic review and meta-analysis. Págs. h1295 TC PDF 

Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell DRisk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. Págs. h1109 TC PDF 


Brauer MAir pollution, stroke, and anxiety. Págs. h1510 TC PDF 

Harrison-Woolrych MMental health effects of varenicline. Págs. h1168 TC (s) PDF (s) 

Steele S, Martyn J, Foell JRisks of the unregulated market in human breast milk. Págs. h1485 TC PDF 


Robertson DP, Keys W, Rautemaa-Richardson R, Burns R, Smith AJManagement of severe acute dental infections. Págs. h1300 TC (s) PDF (s) 

Práctica clínica

Hewitt RJ, Francis M, Singanayagam A, Kon OMScreening tests for tuberculosis before starting biological therapy. Págs. h1060 TC (s) PDF (s) 

Zakrzewska JM, Linskey METrigeminal neuralgia. Págs. h1238 TC (s) PDF (s) 

New England Journal of Medicine. Vol. 372. Núm. 13


Park S, Ahn J, Kim Y, Park D, Yun S, Lee J et al for the BEST Trial InvestigatorsTrial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease. Págs. 1204-1212 TC PDF 

Bangalore S, Guo Y, Samadashvili Z, Blecker S et alEverolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Disease. Págs. 1213-1222 TC (s) PDF (s) 

Vora NM, Li Y, Geleishvili M, Emerson GL, Khmaladze E, Maghlakelidze G et alBrief Report: Human Infection with a Zoonotic Orthopoxvirus in the Country of Georgia. Págs. 1223-1230 TC (s) PDF (s) 


Martin DF, Maguire MGTreatment Choice for Diabetic Macular Edema. Págs. 1260-1261 TC (s) PDF (s) 

Harrington RASelecting Revascularization Strategies in Patients with Coronary Disease. Págs. 1261-1263 TC PDF 


Weaver SC, Lecuit MChikungunya Virus and the Global Spread of a Mosquito-Borne Disease. Págs. 1231-1239 TC (s) PDF (s) 

Ropper AH, Zafonte RDSciatica. Págs. 1240-1248 TC (s) PDF (s) 


Lander ESCutting the Gordian Helix — Regulating Genomic Testing in the Era of Precision Medicine. Págs. 1185-1186 TC (s) PDF (s) 

Sommers BD, Parmet WEHealth Care for Immigrants — Implications of Obama's Executive Action. Págs. 1187-1189 TC PDF 

Karimi-Shah BA, Chowdhury BAForced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and Nintedanib. Págs. 1189-1191 TC (s) PDF (s) 

The Diabetic Retinopathy Clinical Research NetworkAflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. Págs. 1193-1203 TC (s) PDF (s) 

The Lancet. Vol. 385. Núm. 9973


Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D et alEfficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous. Págs. 1075-1086 R TC (s) PDF (s) 

Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S et alEfficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a rando. Págs. 1087-1097 R TC (s) PDF (s) 

Molina J, Orkin C, Iser DM, Zamora F, Nelson M, Stephan C et al for the PHOTON-2 study teamSofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Págs. 1098-1106 R TC (s) PDF (s) 

Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL et alVirological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Págs. 1107-11315 R TC (s) PDF (s) 

Nallamothu BK, Normand ST, Wang Y, Hofer TP, Brush JE, Messenger JC et alRelation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study. Págs. 1114-1122 R TC (s) PDF (s) 


 Hepatitis C: only a step away from elimination?. Págs. 1045 R TC PDF 


Coleman MP, Allemani CCancer: the elephant in the room. Págs. 1047-1048 R TC (s) PDF (s) 

Gluckman P, Nishtar S, Armstrong TEnding childhood obesity: a multidimensional challenge. Págs. 1048-1050 R TC (s) PDF (s) 

Cornberg M, Manns MPNew kids on the block—step by step to an ideal HCV therapy. Págs. 1050-1052 R TC (s) PDF (s) 

Naggie S, Kim AYPHOTON-2: hope for patients with HIV and HCV co-infection?. Págs. 1052-1054 R TC (s) PDF (s) 

Foster GRShorter treatments for hepatitis C: another step forward?. Págs. 1054-1055 R TC (s) PDF (s) 


Webster DP, Klenerman P, Dusheiko GMHepatitis C. Págs. 1124-1135 R TC (s) PDF (s) 

Wain J, Hendriksen RS, Mikoleit ML, Keddy KH, Ochiai RLTyphoid fever. Págs. 1136-1145 R TC (s) PDF (s) 

Punto de vista

Fätkenheuer G, Hirschel B, Harbarth SScreening and isolation to control meticillin-resistant Staphylococcus aureus: sense, nonsense, and evidence. Págs. 1146-1149 R TC (s) PDF (s) 

JAMA. The Journal of the American Medical Association. Vol. 313. Núm. 12


Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C et alOmbitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial. Págs. 1223-1231 TC (s) 

Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG et alVirologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection. Págs. 1232-1239 TC (s) 

Zaidat OO, Fitzsimmons B, Woodward BK, Wang Z, Killer-Oberpfalzer M, Wakhloo A et alEffect of a Balloon-Expandable Intracranial Stent vs Medical Therapy on Risk of Stroke in Patients With Symptomatic Intracranial Stenosis: The VISSIT Randomized Clinical Trial. Págs. 1240-1248 TC (s) 


Chimowitz MI, Derdeyn CPEndovascular Therapy for Atherosclerotic Intracranial Arterial Stenosis: Back to the Drawing Board. Págs. 1219-1220 TC 

Geisbert TWEmergency Treatment for Exposure to Ebola Virus: The Need to Fast-track Promising Vaccines. Págs. 1221-1222 TC 


Venekamp RP, Thompson MJ, Rovers MMSystemic Corticosteroid Therapy for Acute Sinusitis. Págs. 1258-1259 TC (s) 

Thompson AEHypoglycemia. Págs. 1284 TC 

Punto de vista

Yanovski SZ, Yanovski JANaltrexone Extended-Release Plus Bupropion Extended-Release for Treatment of Obesity. Págs. 1213-1214 TC (s) 

Graham CSHepatitis C and HIV Co-infection: Closing the Gaps. Págs. 1217-1218 TC (s) 

CMAJ-Canadian Medical Association Journal. Vol. 187. Núm. 5


King C, Holmes AFive things to know about …: Cannabinoid hyperemesis syndrome. Págs. 355 TC (s) PDF (s) 

Maisels MJManaging the jaundiced newborn: a persistent challenge. Págs. 335-343 TC (s) PDF (s) 

Annals of Internal Medicine. Vol. 162. Núm. 6


Chhatwal J, Kanwal F, Roberts MS, Dunn MCost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States. Págs. 397-406 TC (s) 

Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T et alCost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus. Págs. 407-419 TC (s) 

Guías de práctica clínica

Chou R for the High Value Care Task Force of the American College of PhysiciansCardiac Screening With Electrocardiography, Stress Echocardiography, or Myocardial Perfusion Imaging: Advice for High-Value Care From the American College of Physicians. Págs. 438-447 TC PDF 

Opinión actual

Shroff GRAcute Myocardial Infarction: What's in a Name?. Págs. 448-449 TC (s) 

Medicina Clínica. Vol. 144. Núm. 6


Angona A, Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Garcia-Pallarols F, Longarón R et alTrombocitemia esencial: características iniciales y factores de riesgo de supervivencia y trombosis en una serie de 214 pacientes. Págs. 247-253 R TC (s) PDF (s) 


Hernández JCPredicción del riesgo de trombosis y de la supervivencia en la trombocitemia esencial. Págs. 257-258 TC (s) PDF (s) 


Villamañán E, Armada E, Ruano MProlongación del intervalo QT inducido por fármacos: ¿conocemos sus riesgos?. Págs. 269-274 R TC (s) PDF (s) 

Artículo especial

Dal-Ré R, Carné XAutorización progresiva: ¿un nuevo camino hacia el acceso temprano de nuevos medicamentos?. Págs. 275-278 TC (s) PDF (s) 

Circulation. Vol. 131. Núm. 12


Cavender MA, Scirica BM, Bonaca MP, Angiolillo DJ, Dalby AJ, Dellborg M et alVorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial. Págs. 1047-1053 R TC PDF 

Lee B, Lim H, Fearon WF, Yong AS, Yamada R, Tanaka S et alInvasive Evaluation of Patients With Angina in the Absence of Obstructive Coronary Artery Disease. Págs. 1054-1060 R TC (s) PDF (s) 

Zwadlo C, Schmidtmann E, Szaroszyk M, Kattih B, Froese N, Hinz H et alAntiandrogenic Therapy With Finasteride Attenuates Cardiac Hypertrophy and Left Ventricular Dysfunction. Págs. 1071-1081 R TC (s) PDF (s) 


Pepine CJMultiple Causes for Ischemia Without Obstructive Coronary Artery Disease: Not a Short List. Págs. 1044-1046 TC (s) PDF (s) 

Artículo especial

Joynt KEHealth Policy and Cardiovascular Medicine: Rapid Changes, Immense Opportunities. Págs. 1098-1105 TC (s) PDF (s) 

Washam JB, Herzog CA, Beitelshees AL, Cohen MG, Henry TD, Kapur NK et al on behalf of American Heart Association Clinical Pharmacology Committee of the Council.. Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome: A Scientific Statement From the American Heart Association. Págs. 1123-1149 TC PDF 

BIT-Butlletí d Informació Terapèutica. Vol. 36. Núm. 12


Fernández-Balsells M, Ricart-Engel WNous tractaments farmacològics per a la diabetis mellitus tipus 2: Els agents incretínics i els agents glucosúrics 2014. Págs. 1-9 PDF 

Thorax. Vol. 70. Núm. 4


Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn SEfficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Págs. 311-319 R TC PDF 


Furber AElectronic cigarettes: reasons to be cautious. Págs. 307-308 TC (s) PDF (s) 

Britton JElectronic cigarettes: pro. Págs. 309-310 TC (s) PDF (s) 


Hox V, Maes T, Huvenne W, Drunen CV, Vanoirbeek JA, Joos G et alA chest physician's guide to mechanisms of sinonasal disease. Págs. 353-358 R TC (s) PDF (s) 

Información Farmacoterapéutica de la Comarca - INFAC. Vol. 23. Núm. 1


 Corticoides nasales. Págs. 1-5 PDF 


R Resumen    TC Texto completo    PDF Portable Document File (Adobe Reader)    RC Resumen comentado    (s) Sólo suscriptores   

Contacto con AP al día:
© MEDIGRAF 2015.
Esta web se dirige exclusivamente a los profesionales del sector médico.